Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
21 May 2020updated 06 Oct 2020 9:45am

Chloroquine trial begins at two UK sites

By Samuel Horti

A global trial that will test whether controversial anti-malarial drugs choloroquine and hydroxychloroquine can prevent Covid-19 infection has begun recruiting participants in the UK.

The drugs will be trialled at 25 sites worldwide on healthcare staff who do not have Covid-19 but are in contact with patients carrying the virus. These include the Sussex University Hospitals in Brighton and the John Radcliffe Hospital in Oxford.

Participants will either be given choloroquine, hydroxychloroquine or a placebo. Results are expected before the end of the year.

The drugs, which have not been proven to reduce risk of infection or treat patients with Covid-19, have been approved for use in multiple countries, including the US and Brazil. This week, US President Donald Trump revealed he was taking hydroxychloroquine as a precaution.

Sign up for The New Statesman’s newsletters Tick the boxes of the newsletters you would like to receive. Quick and essential guide to domestic and global politics from the New Statesman's politics team. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. The New Statesman’s weekly environment email on the politics, business and culture of the climate and nature crises - in your inbox every Thursday. A handy, three-minute glance at the week ahead in companies, markets, regulation and investment, landing in your inbox every Monday morning. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A weekly dig into the New Statesman’s archive of over 100 years of stellar and influential journalism, sent each Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.

Content from our partners
How automation can help telecoms companies unlock their growth potential
The pandemic has had a scarring effect on loneliness, but we can do better
Feel confident gifting tech to your children this Christmas